Darunavir . ethanolate | 10-022

Darunavir . ethanolate | 10-022 | Gentaur UK, US & Europe Distribution

BNR: Chemical

Predicted Molecular Weight: 547.7 . 46.0

Physical State: Lyophilized

Storage Condition: Short Term Storage: +4C. Long Term Storage: -20C. Handling Advice: Keep cool and dry. Use/Stability: Stable for at least 2 years after receipt when stored at -20C.

Alternate Name: TMC114; TMC41629; UIC-94017; HSDB 7788; Prezista

Background: Darunavir ethanolate is a highly potent HIV protease inhibitor (IC50=3-6nM, depending on laboratory HIV-1 strain), an antiretroviral medication used to treat and prevent HIV/AIDS. The ethanolate formulation has some stability advantages compared to the free base Darunavir (Prod. No. AG-CR1-3712) . Darunavir ethanolate is a second generation HIV-1 protease inhibitor that inhibits replication of various laboratory strains and clinical isolates of HIV-1, including those resistant to first generation protease inhibitors. It inhibits cell-free diffusion and cell-to-cell spread of HIV-1 in Jurkat cell populations. Formulations containing darunavir have been used in combination therapy for the treatment of HIV. Shown in a SARS-CoV-2 protease structure model study to potentially bind and inhibit the papain like viral protease (PLVP) of SARS-CoV-2, responsible for COVID-19.

Disclaimer: This product is for research use only.

Purity: greater than or equal to 98% (HPLC)

Formula: C27H37N3O7S . C2H5OH

Source: N/A

Solubility: Soluble in DMSO (10mg/ml) or 100% ethanol (5mg/ml) .

InChi Key: QWSHKNICRJHQCY-VBTXLZOXSA-N

Smiles: NC1=CC=C (S (=O) (N (C[C@@H] (O) [C@H] (CC2=CC=CC=C2) NC (O[C@H]3CO[C@]4 ([H]) [C@@]3 ([H]) CCO4) =O) CC (C) C) =O) C=C1.CCO

RTECS: N/A

Identity: Determined by 1H-NMR.

Merck Index: N/A